The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Multiple Sclerosis Therapy: Human Pluripotent Stem Cell-Derived Neural Precursor Cells
Funder
National Health and Medical Research Council
Funding Amount
$1,775,225.00
Summary
Treatments for Multiple Sclerosis (MS) often have unsatisfactory outcomes. The limited ability of the body to repair damaged nerve tissue highlights a critically important need for MS patients. The long-term goal of our research is to develop a stem cell-based therapy that halts disease progression and repairs damaged nerve tissue. Research efforts will refine techniques to make safe and clinically-compatible cells from human stem cell lines and verify the therapeutic activity of these cells.
RELapses PrevENTion In Chronic Autoimmune Disease: Common Mechanisms And Co-morbidities (RELENT)
Funder
National Health and Medical Research Council
Funding Amount
$499,837.00
Summary
Treatment of people with chronic autoimmune and inflammatory diseases is not optimal, as we do not know how intensively to treat people, and current treatments often have significant side effects. The RELENT program aims, using multiple approaches, to gain a deeper and more useful knowledge of why these diseases are occuring, what might indicate that disease requires more treatment, and which treatments will be most targeted and have the fewest side effects.
NOX Enzymes As Mediators Of Inflammation-triggered Neurodegeneration: Modulating NOX Enzymes As Novel Therapies
Funder
National Health and Medical Research Council
Funding Amount
$994,846.00
Summary
The NEURINOX project aims at identifying novel therapeutic targets for neurodegenerative diseases; an increasing health issue for the ageing Australian population. NADPH oxidases (NOX) enzymes, generate reactive oxygen species, and are key regulators of neuroinflammation. Inflammatory dysregulation is characterized by a change in NOX activity. NEURINOX will expound the links between neuroinflammation, NOX enzyme activity & neurodegenerative diseases to identify novel therapeutic targets to treat ....The NEURINOX project aims at identifying novel therapeutic targets for neurodegenerative diseases; an increasing health issue for the ageing Australian population. NADPH oxidases (NOX) enzymes, generate reactive oxygen species, and are key regulators of neuroinflammation. Inflammatory dysregulation is characterized by a change in NOX activity. NEURINOX will expound the links between neuroinflammation, NOX enzyme activity & neurodegenerative diseases to identify novel therapeutic targets to treat neuroinflammation.Read moreRead less
Platform FoR European Preparedness Against (Re-)emerging Epidemics- Australia
Funder
National Health and Medical Research Council
Funding Amount
$386,463.00
Summary
Infectious diseases rank high among the threats to human wellbeing and prosperity- globalisation, migration, tourism, intensive farming and changing climate enhance the likelihood of emergence of outbreaks of infectious disease. The optimal response to an emerging infectious disease requires the rapid acquisition of new knowledge. This project ensures that Australia can contribute to globally coordinated research that will meet the research challenge associated with any new pandemic infection.
Dengue is a viral infection that is transmitted by mosquitoes in tropical regions of the world, including in northern Australia. For doctors who treat dengue patients, a major unmet need is the ability to predict which patients will develop severe complications and need highly specialized supportive care. This proposal will seek to address this unmet need by examining whether markers of human genetic variation can be used to predict those patients at risk of severe dengue.
An Integrated Analysis Of Gene Expression And Chromosome Copy Number In Malignant Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$421,697.00
Summary
Mesothelioma is an aggressive, asbestos related cancer which causes more than 20,000 deaths worldwide per annum. Mesothelioma is characterised by a long latency between exposure to asbestos and development of the disease, estimated to be between 20 and 40 years. As such, the peak number of cases of mesothelioma is not expected in Australia until 2010, as asbestos use reached its peak in the 1970-80's. In 2010, deaths from mesothelioma will be more common than ovarian cancer and melanoma. This st ....Mesothelioma is an aggressive, asbestos related cancer which causes more than 20,000 deaths worldwide per annum. Mesothelioma is characterised by a long latency between exposure to asbestos and development of the disease, estimated to be between 20 and 40 years. As such, the peak number of cases of mesothelioma is not expected in Australia until 2010, as asbestos use reached its peak in the 1970-80's. In 2010, deaths from mesothelioma will be more common than ovarian cancer and melanoma. This study aims to explore the molecular defects that are involved in initiation and progression of mesothelioma. Using array comparative genomic hybridisation, a technique which allows comparison of the DNA of normal cells with that of cancer cells, we will classify chromosomal changes in the cancer cell and identify candidate genes which are involved in mesothelioma development.Read moreRead less
COMPARE:Collaborative Management Platform For Detection And Analyses Of (Re-) Emerging And Foodborne Outbreaks In Europe
Funder
National Health and Medical Research Council
Funding Amount
$427,959.00
Summary
COMPARE a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology and disease-specific information. The aim is to reduce the impact and cost of disease outbreaks. This project allows Australian researchers to participate in this system of detecting and investigating foodborne disease outbreaks that cross international borders.
Improving Health Outcomes In The Tropical North: A Multidisciplinary Collaboration
Funder
National Health and Medical Research Council
Funding Amount
$5,997,916.00
Summary
Improving Health Outcomes in the Tropical North will strengthen partnerships with research institutions in the NT, Qld, WA, NSW, Vic and SA, by undertaking a research agenda that will help close the gap in Indigenous health disadvantage, protect the north from emerging infectious threats and engage regional neighbours. We will establish a northern Australian network that incorporates Indigenous engagement, mentoring and knowledge translation, and facilitates collaboration with southern partners.
Hendra virus (HeV) cause a disease transmitted from bats to horses which in turn infect humans and other horses. There are no drugs or vaccines for HeV. Since humans are infected by inhalation, a vaccine that can generate antibody in the lung and protect from infection will be ideal. We have found that a natural sugar called mannan used with virus proteins and administered via the nostrils to generate such responses. In this project we will prepare this vaccine and use it in a mouse model of HeV ....Hendra virus (HeV) cause a disease transmitted from bats to horses which in turn infect humans and other horses. There are no drugs or vaccines for HeV. Since humans are infected by inhalation, a vaccine that can generate antibody in the lung and protect from infection will be ideal. We have found that a natural sugar called mannan used with virus proteins and administered via the nostrils to generate such responses. In this project we will prepare this vaccine and use it in a mouse model of HeV infection to see if it can protect the mice.Read moreRead less
RARE-Bestpractices: Best Practices For Management Of Rare Diseases
Funder
National Health and Medical Research Council
Funding Amount
$640,231.00
Summary
Although by definition rare, over 8000 rare diseases affect approximately 1.2 million Australians. Patient care has suffered from fragmented approaches and lack of information available to health professionals. This project brings together major experts on rare diseases to improve the translation of scientific progress into tangible benefits for patients. The ultimate impact of this work will be the significant improvement of health outcomes and quality of life for rare disease patients and redu ....Although by definition rare, over 8000 rare diseases affect approximately 1.2 million Australians. Patient care has suffered from fragmented approaches and lack of information available to health professionals. This project brings together major experts on rare diseases to improve the translation of scientific progress into tangible benefits for patients. The ultimate impact of this work will be the significant improvement of health outcomes and quality of life for rare disease patients and reducing inequality in care.Read moreRead less